Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
World J Surg Oncol ; 17(1): 152, 2019 Aug 31.
Article in English | MEDLINE | ID: mdl-31472673

ABSTRACT

BACKGROUND: In some malignant tumors, a high neutrophil-to-lymphocyte ratio (NLR) is connected with unfavorable prognosis. Nevertheless, the prognostic value of the NLR in gliomas remains disputed. The clinical significance of the NLR in gliomas was investigated in our study. METHODS: The databases, PubMed, Embase, and the Cochrane Library, were searched using words like "glioma," "glioblastoma," "neutrophil-to-lymphocyte ratio," and others through May 2019. We evaluated the significance of NLR on overall survival (OS) of patients with gliomas in our study. RESULTS: Finally, 16 cohorts with 2275 patients were analyzed. The pooled analysis revealed that an elevated NLR was connected with unfavorable OS (hazards ratio (HR): 1.43, 95% confidence interval (CI): 1.27-1.62) outcomes of patients with gliomas. CONCLUSION: A high NLR can be considered a high-risk prognostic factor in gliomas, and more adjuvant chemotherapy should be recommended for high-risk patients.


Subject(s)
Brain Neoplasms/pathology , Glioma/pathology , Lymphocytes/pathology , Neutrophils/pathology , Brain Neoplasms/therapy , Glioma/therapy , Humans , Leukocyte Count , Prognosis
2.
World J Surg Oncol ; 15(1): 68, 2017 Mar 21.
Article in English | MEDLINE | ID: mdl-28327158

ABSTRACT

BACKGROUND: Human epidermal growth factor receptor-2 (HER2) is regarded as an important and promising target in the treatment of HER2-positive breast cancers. However, the correlation of clinicopathological characteristics and prognostic significance of HER2 overexpression in gastric cancer patients remains unclear. Our aim was to clarify this issue. METHODS: Embase, PubMed, and the Cochrane Library were searched for relevant articles published up to May 2016. Outcomes of interest contained sex, age, tumor size, tumor site, tumor node metastasis (TNM) stage, distant metastasis, lymph node metastasis, Lauren's classification, differentiation grade, lymphovascular invasion, neural invasion, and multivariate analysis data for overall survival. RESULTS: A total of 41 studies of 17,494 gastric cancer patients were identified with HER2 test. HER2 positive rate was 19.07% (95% CI = 9.16, 28.98). There existed statistical significance between HER2 overexpression and patients' prognosis (RR = 1.47, 95% CI = 1.09, 1.98). Male patients (OR = 1.48, 95% CI = 1.34, 1.65), proximal tumors (OR = 1.25, 95% CI = 1.07, 1.47), intestinal-type tumors (OR = 3.37, 95% CI = 2.54, 4.47), advanced stage cancers (OR = 1.35, 95% CI = 1.10, 1.66), lymph node metastasis (OR = 1.26, 95% CI = 1.14, 1.41), well-differentiated cancers (OR = 1.79, 95% CI = 1.15, 2.76), and distant metastasis (OR = 1.91, 95% CI = 1.08, 3.38) were correlated with higher HER2 expression rates. However, no statistical differences existed in age, tumor size, lymphovascular invasion, or neural invasion. Subgroup analysis revealed that HER2 expression rates reported in articles from Asian (19.52%) countries were quantitatively higher than those from European (16.91%) areas. Results were consistent with those reports that define HER2 status according to trastuzumab for gastric cancer (ToGA) criteria. CONCLUSION: This study showed that HER2 overexpression was associated with poor prognosis in gastric cancer patients. HER2 positive rates may be associated with sex, tumor site, TNM staging system, distant metastasis, lymph node metastasis, Lauren's classification, and differentiation grade in gastric cancer patients. The HER2 expression rate in Asians may be higher than that in Europeans. This study offers a convenient way for doctors to select patients for relevant HER2 detection and following treatment.


Subject(s)
Biomarkers, Tumor/metabolism , Receptor, ErbB-2/metabolism , Stomach Neoplasms/pathology , Case-Control Studies , Female , Humans , Male , Prognosis , Stomach Neoplasms/metabolism
3.
Clin Chem Lab Med ; 55(2): 284-298, 2017 Feb 01.
Article in English | MEDLINE | ID: mdl-27394044

ABSTRACT

BACKGROUND: Although several studies have explored the genetic polymorphisms of apolipoprotein E (APOE) and their impact on premature coronary artery disease (PCAD), there is still some controversy regarding the significance of their association. Our aim is to estimate the association between APOE polymorphisms and PCAD via meta-analysis. METHODS: All relevant case-control studies and cohort studies published in Chinese or English prior to March 2016 were searched for in electronic databases. Detailed information concerning each piece of literature was independently extracted by two researchers. We used STATA11.0 to process all data and to determine the pooled odds ratio (OR). Altogether, four genetic models were applied to calculate OR and 95% confidence interval (CI): (1) ε2 allele vs. ε3 allele; (2) ε2 carriers vs. ε3/3; (3) ε4 allele vs. ε3 allele; (4) ε4 carriers vs. ε3/3. RESULTS: Eighteen studies concerning APOE polymorphisms and their impact on PCAD were included in the final analysis. The pooled analysis displayed that the ε2 allele and ε2 carriers increased the risk of PCAD significantly among Asians (OR 1.54; 95% CI, 1.09-2.17; OR 1.65; 1.10-2.47), while they showed protective effects on PCAD in Caucasians (OR 0.77; 95% CI, 0.62-0.95; OR 0.69; 0.54-0.89). Subjects with the ε4 allele and ε4 carriers showed significant associations with PCAD (OR 1.62; 95% CI, 1.27-2.06; OR 1.65; 1.27-2.15). CONCLUSIONS: Our investigation supported the fact that the ε2 allele in APOE may appear as a risk factor for PCAD in Asians while a protective factor in Caucasians and that the ε4 allele acted as a genetic risk factor for PCAD.


Subject(s)
Apolipoproteins E/genetics , Coronary Artery Disease/genetics , Polymorphism, Genetic/genetics , Adult , Alleles , Coronary Artery Disease/diagnosis , Female , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...